About: Prognostic value of selected chromosomal abnormalities in multiple myeloma patients treated by thalidomide

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Prognostic value of selected chromosomal abnormalities in multiple myeloma patients treated by thalidomide Goto Sponge NotDistinct Permalink

An Entity of Type : http://linked.opendata.cz/ontology/domain/vavai/Vysledek, within Data Space : linked.opendata.cz associated with source document(s)

Attributes	Values
rdf:type	skos:Concept http://linked.opendata.cz/ontology/domain/vavai/Vysledek
Description	The aim of this prospective study is to investigate if Thalidomide is able to antagonize the impact of cytogenetic negative prognostic markers. We have focused on four chromosomal aberrations known as negative prognostic factors in multiple myeloma (MM) treated by conventional or myeloablastive treatment: deletion of 13q14 (RB), deletion of 17p13 (p53), amplification of CKS1B gene (1q21) and translocation t(4;14). Material and Methods: For identification of malignant plasma cells in bone marrow samples, we use cytoplasmic immunoglobulin (cIg) labelling methodology. This method allows us to identify simultaneously monotypic plasma cells by monoclonal antibody fluorescence (anti-k or anti-l) and to detect chromosomal abnormalities by fluorescence in situ hybridization (cIg-FISH). Overall characteristics of up-to-date set of 24 patients (pts.): median age 65,0 years (range 48,3-83,3). 66% (16/24 pts.) in stage IIIA, 29% (7/24 pts.) in stage IIA and 1 patient in IIIB. 75% (16/24 pts. The aim of this prospective study is to investigate if Thalidomide is able to antagonize the impact of cytogenetic negative prognostic markers. We have focused on four chromosomal aberrations known as negative prognostic factors in multiple myeloma (MM) treated by conventional or myeloablastive treatment: deletion of 13q14 (RB), deletion of 17p13 (p53), amplification of CKS1B gene (1q21) and translocation t(4;14). Material and Methods: For identification of malignant plasma cells in bone marrow samples, we use cytoplasmic immunoglobulin (cIg) labelling methodology. This method allows us to identify simultaneously monotypic plasma cells by monoclonal antibody fluorescence (anti-k or anti-l) and to detect chromosomal abnormalities by fluorescence in situ hybridization (cIg-FISH). Overall characteristics of up-to-date set of 24 patients (pts.): median age 65,0 years (range 48,3-83,3). 66% (16/24 pts.) in stage IIIA, 29% (7/24 pts.) in stage IIA and 1 patient in IIIB. 75% (16/24 pts. (en)
Title	Prognostic value of selected chromosomal abnormalities in multiple myeloma patients treated by thalidomide Prognostic value of selected chromosomal abnormalities in multiple myeloma patients treated by thalidomide (en)
skos:prefLabel	Prognostic value of selected chromosomal abnormalities in multiple myeloma patients treated by thalidomide Prognostic value of selected chromosomal abnormalities in multiple myeloma patients treated by thalidomide (en)
skos:notation	RIV/00216224:14110/07:00022773!RIV10-MSM-14110___
http://linked.open...avai/riv/aktivita	P Z
http://linked.open...avai/riv/aktivity	P(LC06027), Z(MSM0021622415)
http://linked.open...vai/riv/dodaniDat	2010
http://linked.open...aciTvurceVysledku	Pour, Luděk Kuglík, Petr Krejčí, Marta Hájek, Roman Adam, Zdeněk Němec, Pavel Filková, Hana Oltová, Alexandra Křivanová, Andrea Grešliková, Henrieta Zaoralová, Romana
http://linked.open.../riv/druhVysledku	D - Článek ve sborníku
http://linked.open...iv/duvernostUdaju	S - Úplné a pravdivé údaje nepodléhající ochraně podle zvláštních právních předpisů
http://linked.open...titaPredkladatele	Masarykova univerzita / Lékařská fakulta
http://linked.open...dnocenehoVysledku	445066
http://linked.open...ai/riv/idVysledku	RIV/00216224:14110/07:00022773
http://linked.open...riv/jazykVysledku	eng - angličtina
http://linked.open.../riv/klicovaSlova	Multiple myeloma; thalidomide; cIg FISH (en)
http://linked.open.../riv/klicoveSlovo	thalidomide cIg FISH Multiple myeloma
http://linked.open...ontrolniKodProRIV	[80C8A44AC117]
http://linked.open...v/mistoKonaniAkce	Kos Island, Greece
http://linked.open...i/riv/mistoVydani	Pavia (Italy)
http://linked.open...i/riv/nazevZdroje	Haematologica
http://linked.open...in/vavai/riv/obor	EB
http://linked.open...ichTvurcuVysledku	11 (xsd:int)
http://linked.open...cetTvurcuVysledku	11 (xsd:int)
http://linked.open...vavai/riv/projekt	University Research Centre - Czech Myeloma Group
http://linked.open...UplatneniVysledku	2007
http://linked.open...iv/tvurceVysledku	Adam, Zdeněk Hájek, Roman Krejčí, Marta Kuglík, Petr Pour, Luděk Němec, Pavel Filková, Hana Oltová, Alexandra Grešliková, Henrieta Křivanová, Andrea Zaoralová, Romana
http://linked.open...vavai/riv/typAkce	EUR - Evropská
http://linked.open.../riv/zahajeniAkce	2007-07-25 (xsd:date)
http://linked.open...n/vavai/riv/zamer	Molecular basis of cell and tissue regulations
issn	0390-6078
number of pages	1 (xsd:int)
http://purl.org/ne...btex#hasPublisher	Ferrata-Storti foundation
http://localhost/t...ganizacniJednotka	14110
is http://linked.open...avai/riv/vysledek of	Prognostic value of selected chromosomal abnormalities in multiple myeloma patients treated by thalidomide Prognostic value of selected chromosomal abnormalities in multiple myeloma patients treated by thalidomide Prognostic value of selected chromosomal abnormalities in multiple myeloma patients treated by thalidomide

Faceted Search & Find service v1.16.118 as of Jun 21 2024

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3240 as of Jun 21 2024, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (126 GB total memory, 112 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software